Mandate

Vinge advises EQT VII in its acquisition of Eton Group AB

December 30, 2015

Vinge advises EQT VII in its acquisition of Eton Group AB and its subsidiaries in Sweden, the US, Canada and the UK (together “Eton”) from Litorina IV and a number of minority shareholders. Founded in Gånghester, Sweden, in 1928, Eton is today a global premium men’s shirts brand, offering shirts and directly linked accessories. Eton primarily sells through department stores, complemented with five own brand stores and its own online store. Eton is still headquartered in Gånghester and has approximately 155 employees across the world. The transaction is conditional upon approval from competition authorities and is expected to close in early 2016.

Vinge’s team consists of partners Christina Kokko and Peter Sundgren together with associates Sofie Bjärtun and Adriana Berglund (both M&A), Karin Virding (IP), Parul Sharma and Linn Gustavsson (both CSR), Karin Isacsson (employment), Nicklas Thorgezon (IT), Jasmin Draszka-Ali, Ulrich Ziche and Maria Dahlin (agreements), Adam Sandberg (financing), Anna Lonergran (real property), Helena Höök (competition law) as well as project assistant Josefin Backlund. Partner Marcus Glader and associates Grant McKelvey and Johanna Bjurling advice in relation to merger filing.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025